Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China: A Nation-wide, Multi-center, Prospective, Non-interventional Study
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms RECOVER
- Sponsors Daiichi Sankyo Company
Most Recent Events
- 10 Mar 2025 Status changed from not yet recruiting to recruiting.
- 03 Mar 2025 New trial record